Abivax Unveils Obefazimod’s Anti-Fibrotic Effects at ECCO 2026 Congress
Abivax SA presented first evidence of anti-fibrotic activity for its drug obefazimod in preclinical models of inflammatory bowel disease at the European Crohn's and Colitis Organization's 21st Annual Congress. The company also shared new clinical efficacy and safety data from Phase 3 trials, bolstering the drug's profile for ulcerative colitis and Crohn's disease.